Research Article| Volume 163, ISSUE 1, P25-31, February 01, 1999

Download started.


Pramipexole — a new dopamine agonist for the treatment of Parkinson's disease


      Although l-DOPA is the current `gold standard' for treatment of Parkinson's disease, its effectiveness fades rapidly and its use results in serious motor fluctuations (on-off, wearing off, freezing, involuntary movements) for most patients with Parkinson's disease. Pramipexole is an aminothiazole dopamine agonist with selective actions at dopamine receptors belonging to the D2 subfamily, where it possesses full activity similar to dopamine itself. Pramipexole's preferential affinity for the D3 receptor subtype could contribute to efficacy in the treatment of both the motor and psychiatric symptoms of Parkinson's disease. Both in vitro and in vivo studies in animals suggest that pramipexole possesses numerous neuroprotective properties, including dopamine autoreceptor agonist properties, antioxidant properties, ability to block the mitochondrial permeability transition pore and the ability to stimulate the release of trophic factors. Clinical studies have demonstrated that pramipexole has excellent pharmacokinetic properties and that it is an effective monotherapy in treating early Parkinson's disease and an effective adjunctive therapy with l-DOPA in treating late Parkinson's disease. In addition, pramipexole has demonstrated efficacy in a clinical trial for the treatment of major depression. In the early disease studies, pramipexole was able to retard the need for l-DOPA treatment for several years. Thus, a new `l-DOPA-sparing' paradigm for treating Parkinson's disease may now be possible, whereby patients are initially treated with pramipexole and l-DOPA is added only as necessary.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Blanchet P.J
        • Calon F
        • Martel J.C
        • Bedard P.J
        • DiPaolo T
        • Walters R.R
        • Piercey M.F
        Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D-2 agonist (U-91356A) in MPTP monkeys.
        J Pharmacol Exp Ther. 1995; 272: 854-859
        • Bouthenet M.L
        • Souil E
        • Martres M.-P
        • Sokoloff P
        • Giros B
        • Schwartz J.-C
        Localization of a dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA.
        Brain Res. 1991; 564: 203-219
        • Carvey P.M
        • Pieri S
        • Ling Z.D
        Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.
        J Neural Transm. 1997; 104: 209-228
        • Cassarino D.S
        • Fall C.P
        • Smith T.S
        • Bennett Jr., J.P
        Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion.
        J Neurochem. 1998; 71: 295-301
        • Civelli O
        • Buznow J.R
        • Grandy K.D
        Molecular diversity of the dopamine receptors.
        Ann Rev Pharmacol Toxicol. 1993; 32: 281-307
      1. Corrigon M, Piercey M, Sullivan H, Gomez-Mancilla B, Denahan A. The role of dopamine in depression. Am. J. Geriatr Psychiatry, in press.

        • Cummings J.L
        Depression and Parkinson's disease: A review.
        Am J Psychiatry. 1992; 149: 443-454
        • Gerfen C.R
        The neostriatal mosaic: multiple levels of compartmental organization.
        Trends Neurosci. 1992; 15: 133-139
        • Hall E.D
        • Andrus P.K
        • Oostveen J.A
        • Althaus Vo, J.S
        • VonVoigtlander P.F
        Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.
        Brain Res. 1996; 742: 80-88
        • Hoffmann W.E
        • Piercey M.F
        Dopamine D2 and D3 receptor subtypes mediate excitatory and inhibitory responses respectively in rat SNPR.
        Soc. Neurosci Abs. 1996; 22: 219
        • Hoffmann W.E
        • Smith M.W
        • Piercey M.F
        Electrophysiological evidence associating limbic preference with pramipexole, a D3-preferring dopamine agonist.
        Soc Neurosci Abs. 1995; 21: 1142
        • Hu X.-T
        • Wang R.Y
        Comparison of the effects of D1 and D2 dopamine receptor agonists on neurons in the rat caudate putamen: An electrophysiological study.
        J Neurosci. 1988; 8: 4340-4348
        • Kitamura Y
        • Kohno Y
        • Nakaazawa M
        • Nomura Y
        Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.
        Jpn J Pharmacol. 1997; 74: 51-57
        • Lieberman A
        • Ranhosky A
        • Korts D
        Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study.
        Neurology. 1997; 49: 162-168
        • Maj J
        • Rogoz A
        • Skuza G
        • Kofodziejczyk K
        Antidepressant effects of pramipexole, a novel dopamine receptor agonist.
        J Neural Transm. 1997; 104: 525-533
        • Mierau J
        • Schingnitz G
        Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2-receptor agonist.
        Eur J Pharmacol. 1992; 215: 161-170
        • Mierau J
        • Schneider F.J
        • Ensinger H.A
        • Chio C.L
        • Lajiness M.E
        • Huff R.M
        Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
        Eur J Pharmacol. 1995; 290: 29-36
        • Moore H
        • Todd C.L
        • Grace A.A
        Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons.
        J Neurosci. 1998; 18: 5068-5077
        • Murer M.G
        • Dziewczapolski G
        • Menalled L.B
        • Garcia M.C
        • Agid Y
        • Gershanik O
        • Raisman-Vozari R
        Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
        Ann Neurol. 1998; 43: 561-575
        • Olanow C.W
        Attempts to obtain neuroprotection in Parkinson's disease.
        Neurology. 1997; 49: S26-S33
      2. Parkinson Study Group. Effects of tocopherol and deprenyl in progression of disability in early Parkinson's disease. New Engl J Med 1993;328:176–183.

      3. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37–45.

      4. Parkinson Study Group. A survey of antidepressant drug use in Parkinson's disease. Neurology 1997;49:1168–1170.

      5. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. J Am Med Assoc 1997;278:125–30.

        • Piercey M.F
        • Hoffmann W.E
        • Smith M.W
        • Hyslop D.K
        Inhibition of dopamine neuron firing by pramipexole, a D3-preferring dopamine agonist: Comparison to other dopamine agonists.
        Eur J Pharmacol. 1996; 312: 35-44
        • Piercey M.F
        • Hyslop D.K
        • Hoffmann W.E
        Excitation of type II anterior caudate neurons by stimulation of D3 receptors.
        Brain Res. 1997; 762: 19-28
        • Shannon K.M
        • Bennett Jr., J.P
        • Friedman J.H
        Efficacy of pramipexole, a novel dopamine agonist, in mild to moderate Parkinson's disease. The Pramipexole Study Group.
        Neurology. 1997; 49: 724-728
        • Skirboll L.R
        • Grace A.A
        • Bunney B.S
        Dopamine auto- and postsynaptic receptors: Electrophysiological evidence for differential sensitivity to dopamine agonists.
        Science. 1979; 206: 80-82
        • Surmeir D.J
        • Song W.J
        • Yan Z
        Coordinated expression of dopamine receptors in neostriatal medium spiny neurons.
        J Neurosci. 1996; 16: 6579-6591
        • Szegedi A
        • Wetzel J
        • Hillert A
        • Kleiser E
        • Gaebel W
        • Benkert O
        Pramipexole, a novel selective dopamine agonist in major depression.
        Mov Disord. 1996; 11: 266
        • Willner P
        • Lappas S
        • Cheeta S
        • Muscat R
        Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole.
        Psychopharmacology (Berl). 1994; 115: 454-462
        • Wright C.E
        • Sisson T.L
        • Ichhpurani A.K
        • Peters G.R
        Steady-state pharmacokinetic properties of pramipexole in healthy volunteers.
        J Clin Pharmacol. 1997; 37: 520-525
        • VonVoigtlander P.F
        • Fici G.J
        • Althaus J.S
        Pharmacological approaches to counter the toxicity of dopa.
        Amino Acids. 1998; 14: 189-196
        • Yurek D.M
        • Hipkens S.B
        • Herbert M.A
        • Gash D.M
        • Gerhardt G.A
        Age-related decline in striatal dopamine release and motoric function in brown Norway/Fischer 344 hybrid rats.
        Brain Res. 1998; 791: 246-256